Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
Back to dashboard
Company Information
About this company
Key people
Michael Graves
Interim Executive Chairman of the Board, Interim Principal Executive Officer
Christopher Krawtschuk
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Steven B. Ratoff
Director
Luciana Borio
Independent Director
Richard A. Edlin
Independent Director
Robert L. Glenning
Independent Director
Jennifer K. Simpson
Independent Director
Click to see more
Key facts
- Shares in issue17.54m
- EPICEGRX
- ISINUS2697961082
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$11.49m
- Employees134
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.